KORTH CARSTEN has a total of 27 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2003. It filed its patents most often in WIPO (World Intellectual Property Organization), Germany and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are JAPAN PRESIDENT UNIV TOKYO, COMO BIOTECH APS and GENEMEDIX PLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 10 | |
#2 | Germany | 5 | |
#3 | EPO (European Patent Office) | 5 | |
#4 | United States | 5 | |
#5 | Canada | 1 | |
#6 | China | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Analysing materials | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Medical preparations | |
#5 | Measuring microorganism processes | |
#6 | Heterocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Korth Carsten | 26 |
#2 | Bader Verian | 7 |
#3 | Leliveld Sirik Rutger | 5 |
#4 | Petsch Benjamin | 4 |
#5 | Hecher Laura | 4 |
#6 | Trossbach Svenja | 4 |
#7 | Stitz Lothar | 4 |
#8 | Klingenstein Ralf | 3 |
#9 | Leliveld S Rutger | 3 |
#10 | Leliveld Rutger S | 3 |
Publication | Filing date | Title |
---|---|---|
EP3327134A1 | Method and biomarkers for in vitro diagnosis of mental disorders | |
DE102011016875A1 | A preparation comprising DISC1 and / or at least one DISC1 fragment for use in the therapeutic treatment of the human or animal body | |
DE102010018561A1 | Quantitative markers for determining the mental status of a subject | |
US2009209516A1 | 9-amino-acridine derivatives and method of treating autoimmune diseases using the same | |
DE102008016064A1 | Method for the diagnosis and treatment of chronic psychiatric disorders as well as markers and targets for such procedures | |
DE102007022669A1 | Use of CRMP1 as a marker for chronic psychiatric disorders | |
DE102007022670A1 | Use of CRMP1 as a target for chronic psychiatric disorders |